Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
ABVX · Why this verdict
Why Abivax (ABVX) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Abivax is a clinical-stage biotech burning cash at 2,697% of revenue with repeated earnings misses, offset by 89% analyst upside and a reward-to-risk of 6.89 after a 42% drawdown.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Free cash flow is -2697% of revenue and the Rule of 40 reads -2704 (fail), holding the quality score at 3.7 against a 4.0 floor. Quality breakdown | Cash burn should be fundable and revenue should begin to scale over the next 12 months. | →Stable |
| CounterFor a clinical-stage biotech, cash burn funds development of the pipeline, and the current ratio component of 7.0 shows liquidity is adequate. | ||
The analyst target of $142.32 implies 64.4% upside from $86.59 against 9.3% downside (reward-to-risk 6.89), with analysts seeing 89% upside before haircut. Targets | Price should move toward the analyst target if clinical milestones are met. | →Stable |
| CounterBiotech outcomes are binary, and a single trial setback could erase the upside regardless of analyst targets. | ||
Abivax missed estimates in 3 of the last 4 quarters, most recently a loss of $1.69 per share versus $0.86 expected, for an average surprise of -77.8%. Earnings | Losses should come in at or better than consensus over the next two reports. | →Stable |
| CounterBiotech loss estimates are volatile and lumpy because of trial and manufacturing spend timing, and the May 2026 quarter beat. | ||
Price is below a 200-day average sloping down 4.1% per 30 days with falling OBV, after a 42% drawdown from the 52-week high. Momentum breakdown | Price should reclaim the 200-day average and momentum should rise above 4.5. | ↑Improving |
| CounterMACD is at 10/10 and the setup is classified as recovery, which suggests selling pressure is easing. | ||
Revenue is declining 7% and the quality rank versus peers is 0.0, though the company carries conservative debt levels. Growth breakdown | Revenue should stabilize or grow above 0% YoY as the company moves toward commercialization. | →Stable |
| CounterRevenue in a pre-commercial biotech is typically collaboration or grant income and is not a good measure of progress. | ||
Free cash flow is -2697% of revenue and the Rule of 40 reads -2704 (fail), holding the quality score at 3.7 against a 4.0 floor.
→StableQuality breakdown
- Expectation
- Cash burn should be fundable and revenue should begin to scale over the next 12 months.
CounterFor a clinical-stage biotech, cash burn funds development of the pipeline, and the current ratio component of 7.0 shows liquidity is adequate.
The analyst target of $142.32 implies 64.4% upside from $86.59 against 9.3% downside (reward-to-risk 6.89), with analysts seeing 89% upside before haircut.
→StableTargets
- Expectation
- Price should move toward the analyst target if clinical milestones are met.
CounterBiotech outcomes are binary, and a single trial setback could erase the upside regardless of analyst targets.
Abivax missed estimates in 3 of the last 4 quarters, most recently a loss of $1.69 per share versus $0.86 expected, for an average surprise of -77.8%.
→StableEarnings
- Expectation
- Losses should come in at or better than consensus over the next two reports.
CounterBiotech loss estimates are volatile and lumpy because of trial and manufacturing spend timing, and the May 2026 quarter beat.
Price is below a 200-day average sloping down 4.1% per 30 days with falling OBV, after a 42% drawdown from the 52-week high.
↑ImprovingMomentum breakdown
- Expectation
- Price should reclaim the 200-day average and momentum should rise above 4.5.
CounterMACD is at 10/10 and the setup is classified as recovery, which suggests selling pressure is easing.
Revenue is declining 7% and the quality rank versus peers is 0.0, though the company carries conservative debt levels.
→StableGrowth breakdown
- Expectation
- Revenue should stabilize or grow above 0% YoY as the company moves toward commercialization.
CounterRevenue in a pre-commercial biotech is typically collaboration or grant income and is not a good measure of progress.
Per-dimension breakdown
Quality
3.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 10.0 |
| Net margin | 0.0 |
| Current ratio | 7.0 |
| FCF quality | 0.0 |
| Moat | 5.5 |
| Rule of 40 | 3.0 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -2697% of revenue
- ▸Rule of 40: -2704 (fail)
Growth
0.8/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 0.8 |
- ▸Declining revenue: -7%
Momentum
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 4.0 |
| Volume | 2.1 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -4.5%/30d — confirmed downtrend
Sentiment
6.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 9.9 |
| erm sentiment | 5.0 |
- ▸Analyst upside: 81%
Insider
5.0/10data confidence 50%Peer rank
4.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 0.0 |
| growth rank | 2.8 |
- ▸Conservative debt levels
Technical
3.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.3 |
| support resistance | 4.8 |
| 52w position | 2.1 |
Risk (lower is worse)
6.1/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.6 |
| days to cover | 6.8 |
| volatility | 2.4 |
| put call | 6.6 |
| implied vol | 2.1 |
| max pain risk | 7.0 |
| debt equity | 10.0 |
- ▸High IV: 67%
Catalyst
2.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:QUALITY_FLOORPassed (8)
- MOMENTUM:6.1>=5.5
- ASYMMETRY:7.1>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:130d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (1)
- DEATH_CROSS:momentum=6.1>=5.0 recovering
Reward-to-Risk
7.13
Upside
+57.8%
Downside
8.1%
Sizing output
AVOID
SetupRecovery — Death cross but MACD improving, RSI 54
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.0 and asymmetric R:R of 7.13.
The strongest dimensions are Value at 9.0, Sentiment at 6.6, and Momentum at 6.1; the weakest are Growth at 0.8, Catalyst at 2.5, and Technical at 3.4. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 7.13 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Extreme Cash Burn
Trip ifFree cash flow falls below -4000% of revenue from current -2697%.
- P2Large Analyst Upside Binary Outcome
Trip ifPrice falls below the $81.59 stop level, more than 5% below current $86.59.
- P3Persistent Earnings Misses
Trip ifEPS surprise stays below -25% for 2 consecutive quarters.
- P4Confirmed Downtrend
Trip ifMomentum score falls below 2.5 from current 3.7.
- P5Declining Revenue Weak Peer Quality
Trip ifRevenue decline exceeds 20% YoY from current -7%.